Zeynep OZGEN ERDOĞMUŞ, MERAL ERDİNÇ, HASAN AKKOÇ, İlker KELLE

Protective effects of melatonin on doxorubicin induced cardiotoxicity in isolated rat heart

Doxorubicin is a highly effective cancer chemotherapeutic agent and its clinical use is limited by its serious cardiotoxicity. Oxidative damage is suggested to play a major role in its cardiotoxicity. In this study we aimed to research the protective effects of melatonin-which is a free radical scavenger and antioxidant -on Doxorubicin-induced cardiotoxicity in isolated perfused rat heart. Male wistar albino rats were divided into four groups: 1.group: control (1ml (i.p) sterile saline), 2.group: Doxorubicin (Dox) (one dose, 10 mg/kg (i.p)), 3.group: Dox (one dose, 10 mg/kg (i.p)) + Melatonin (Mel) for 7 days once a day 10 mg/kg (i.p)), 4.group: Melatonin (for 7 days once a day 10 mg/kg (i.p)). After 7 days, the hearts were isolated and perfused by Langendorff system. Heart rate, coronary perfusion pressure, Left ventricular developed pressure (LVDP), LV (dP/dt)max and LV(dP/dt)min which shows max and min pressures during systole and diastole per time were recorded. As a result; a significant increase in coronary perfusion pressure and LV(dP/dt)min and also a significant decrease in LVDP, LV(dP/dt)max and heart rates in the Dox group according to control group showed altered cardiac functions induced by Dox. versus the Dox group, in the Dox+Mel group the coronary perfusion pressure and LV(dP/dt)min significantly decreased and LVDP and LV(dP/dt)max significantly increased. So it is concluded that melatonin has protective effects on doxorubicin induced cardiotoxicity characterized with altered heart contractility and hemodynamics.

___

1. Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012; 52: 1213-1225.

2. Tokarska-Schlattner M, Zaugg M, Zuppinger C, et al. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006; 41: 389-405.

3. Menna P, Alberto Sordi F. Antrasiklin Degration in Cardiomyocytes: A Journey to Oxidative Survival, Chem. Res. Toxicol 2010; 23: 6-10.

4. Simunek T, Sterba M, Popelova O, et al. Anthracycline induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61: 154-171.

5. Bates SE, Rosing DR, Fojo T, Piekarz RL. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res 2006; 12: 3871-3874.

6. Li T, Danelisen I, Singal PK. Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. Mol Cell Biochem 2002; 232: 19-26.

7. Suliman HB, Carraway MS, Ali AS, et al. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest 2007; 117: 3730-3741.

8. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006; 33: 2-7.

9. Deng S, Kruger A, Kleschyov AL, et al. Gp91phoxcontaining NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med 2007; 42: 466-473.

10. Hrenák J, Arendásová K, Rajkovicová R, et al. Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin- induced nephrotoxicity in rats. Physiol Res 2013; 62: 181-189.

11. Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004; 37: 837-846.

12. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.

13. Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin's metabolites. AFMK and AMK. J Pineal Res 2013; 54: 245-257.

14. García JJ, López-Pingarrón L, Almeida-Souza P, et al. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res 2014; 56: 225-237.

15. Cuzzocrea S, Reiter RJ. Pharmacological action of melatonin in shock, inflammation and ischemia reperfusion injury. Eur J Pharmacol 2001; 426: 1- 10.

16. Poun P, Bonoron-Adele S, Gouverneur G, Traiosse L. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 1996; 117: 1593- 1599.

17. Tengattini S, Reiter RJ, Tan DX, et al. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44: 16-25.

18. Vora J, Khaw BA, Narula J, Boroujerdi M. Protective effect of butylated hydroxyanisole on adriamycin-induced cardiotoxicity. J. Pharm. Pharmacol 1996; 48: 940-944.

19. Tong J, Ganguly PK, Singal PK. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 1991; 260: 909-916.

20. De Nigris F, Rienzo M, Schiano C, et al. Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. Eur J Cancer 2008; 44: 334-340.

21. Nishiyama K, Yasue H, Moriyama Y, et al. Acute effects of melatonin administration on cardiovascular autonomic regulation in healty men. Am Heart J 2001; 141: 149.

22. Morishima I, Okumura K, Matsui H, et al. Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of cardioprotective antioxidant. J Pineal Res 1999; 26: 204-210.

23. Reiter RJ, Tan DX. Melatonin: Anovel protective agentgainst oxidative injury of the ischemicreperfused heart. Cardiovascular Research 2003; 58: 10-19.

24. Neilan TG, Blake SL, Ichinose F, et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007; 116: 506-514.

25. Sahna E, Parlakpinar H, Ozturk F, et al. Melatonin protects against myocardial doxorubicin toxicity in rats: Role of physiological concentrations. J Pineal Res 2003; 35: 257-261.